Tedatioxetine

Tedatioxetine
Clinical data
Other namesLu AA24530; Lu-AA-24530
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC18H21NS
Molar mass283.43 g·mol−1
3D model (JSmol)
  • CC(C=C1)=CC=C1SC2=C(C3CCNCC3)C=CC=C2
  • InChI=1S/C18H21NS/c1-14-6-8-16(9-7-14)20-18-5-3-2-4-17(18)15-10-12-19-13-11-15/h2-9,15,19H,10-13H2,1H3 checkY
  • Key:CVASBKDYSQKLSO-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Tedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant that was discovered by scientists at Lundbeck; in 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.

Tedatioxetine is reported to act as a triple reuptake inhibitor (serotonin > norepinephrine > dopamine) and 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptor antagonist.

As of 2009, it was in phase II clinical trials for major depressive disorder, but there have been no updates since then, and as of August 2013 it was no longer displayed on Lundbeck's product pipeline.

On May 10, 2016, all work on tedatioxetine stopped.

A Chinese patent shows that there has been interest in this compound outside of Lundbeck.

See also



This page was last updated at 2024-01-25 12:59 UTC. Update now. View original page.

All our content comes from Wikipedia and under the Creative Commons Attribution-ShareAlike License.


Top

If mathematical, chemical, physical and other formulas are not displayed correctly on this page, please useFirefox or Safari